2-溴-6-甲基-4-硝基苯胺 | 102170-56-9

• 物质功能分类: 有机原料 - 氨基化合物 - 环烷胺、芳香单胺、芳香多胺及其衍生物和盐
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 2-溴-6-甲基-4-硝基苯胺
• 英文名称: 2-bromo-6-methyl-4-nitroaniline
• 英文别名: 2-amino-3-bromo-5-nitrotoluene
• CAS: 102170-56-9
• 化学式: C₇H₇BrN₂O₂
• mdl: MFCD00053089
• 分子量: 231.049
• InChiKey: DCNWQCOXGLGSRC-UHFFFAOYSA-N

物化性质

• 熔点：
  180-184 °C
• 沸点：
  366.0±37.0 °C(Predicted)
• 密度：
  1.7207 (rough estimate)
• 稳定性/保质期：
  遵照规定使用和储存，则不会发生分解。

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  12
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  71.8
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 危险等级：
  IRRITANT
• 危险品标志：
  Xi
• 安全说明：
  S36/37
• 危险类别码：
  R20/21/22
• WGK Germany：
  3
• 海关编码：
  2921430090
• 危险类别：
  IRRITANT
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335
• 储存条件：
  存于阴凉干燥处。

SDS

Name:	2-Bromo-6-methyl-4-nitroaniline Material Safety Data Sheet
Synonym:
CAS:	102170-56-9

Section 1 - Chemical Product MSDS Name:2-Bromo-6-methyl-4-nitroaniline Material Safety Data Sheet
Synonym:

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
102170-56-9	2-Bromo-6-methyl-4-nitroaniline		unlisted

Hazard Symbols: XN
Risk Phrases: 20/21/22

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Harmful by inhalation, in contact with skin and if swallowed.
Potential Health Effects
Eye:
May cause eye irritation.
Skin:
May cause skin irritation. Harmful if absorbed through the skin.
Ingestion:
Harmful if swallowed. May cause irritation of the digestive tract.
Inhalation:
Harmful if inhaled. May cause respiratory tract irritation.
Chronic:
Not available.

---

Section 4 - FIRST AID MEASURES
Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Ingestion:
Get medical aid. Wash mouth out with water.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen.
Notes to Physician:

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or chemical foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container.

---

Section 7 - HANDLING and STORAGE
Handling:
Avoid breathing dust, vapor, mist, or gas. Avoid contact with skin and eyes.
Storage:
Store in a cool, dry place. Store in a tightly closed container.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 102170-56-9: Personal Protective Equipment Eyes: Not available.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Solid
Color: off-white
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 180-181 deg C
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C7H7BrN2O2
Molecular Weight: 231.05

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Not available.
Conditions to Avoid:
Incompatible materials.
Incompatibilities with Other Materials:
Strong oxidizing agents.
Hazardous Decomposition Products:
Carbon monoxide, oxides of nitrogen, carbon dioxide, hydrogen bromide.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 102170-56-9 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
2-Bromo-6-methyl-4-nitroaniline - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
No information available.
IMO
No information available.
RID/ADR
No information available.

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: XN
Risk Phrases:
R 20/21/22 Harmful by inhalation, in contact with
skin and if swallowed.
Safety Phrases:
S 26 In case of contact with eyes, rinse immediately
with plenty of water and seek medical advice.
S 37/39 Wear suitable gloves and eye/face
protection.
WGK (Water Danger/Protection)
CAS# 102170-56-9: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 102170-56-9 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 102170-56-9 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  2-溴-6-甲基-4-硝基苯胺 在 乙醇 、 硝酸 、 亚硝酸 、 铁粉 、 溶剂黄146 作用下， 生成 2,3-二溴苯甲酸
  参考文献：
  名称：

  Nevile; Winther, Chemische Berichte, 1880, vol. 13, p. 963

  摘要：

  DOI：
• 作为产物：
  描述：

  4-硝基-2-甲苯胺 在 benzyltrimethylammonium tribromide 、 calcium carbonate 作用下， 以 甲醇 、 二氯甲烷 为溶剂， 反应 0.5h， 以91%的产率得到2-溴-6-甲基-4-硝基苯胺
  参考文献：
  名称：

  使用季铵多卤化物的卤化。六、苄基三甲基三溴化铵溴化芳香胺

  摘要：

  芳香胺与三溴化苄基三甲基铵在含有碳酸钙粉末的二氯甲烷-甲醇中在室温下反应 0.5 小时，以良好的收率得到溴取代的芳香胺。

  DOI：

  10.1246/bcsj.61.597

文献信息

• [EN] AZABENZIMIDAZOLES AND THEIR USE AS AMPA RECEPTOR MODULATORS<br/>[FR] AZABENZIMIDAZOLES ET LEUR UTILISATION EN TANT QUE MODULATEURS DES RÉCEPTEURS AMPA
  申请人：JANSSEN PHARMACEUTICA NV

  公开号：WO2016176460A1

  公开（公告）日：2016-11-03

  Provided herein are compounds of Formula (I), and pharmaceutically acceptable salts, N-oxides, or solvates thereof, [formula (I) should be inserted here]. Also provided herein are pharmaceutical compositions comprising compounds of Formula (I) and methods of using compounds of Formula (I).

  本文件提供了公式(I)的化合物，以及药学上可接受的盐、N-氧化物或溶剂化物[此处应插入公式(I)]。此外，还提供了包含公式(I)化合物的药物组合物以及使用公式(I)化合物的方法。
• Intramolecular Remote C–H Activation via Sequential 1,4-Palladium Migration To Access Fused Polycycles
  作者：Panpan Li、Qiuyu Li、He Weng、Jiaming Diao、Hequan Yao、Aijun Lin

  DOI：10.1021/acs.orglett.9b02392

  日期：2019.9.6

  conveyor has been described. This reaction provides an efficient route to construct diverse polycyclic frameworks in moderate to good yield via palladium-catalyzed remote C-H activation/alkene insertion, arylation, alkenylation, and the Heck reaction. The preliminary mechanistic studies revealed that the 1,4-palladium migration process was reversible.

  已经描述了空前的分子内远程CH活化，其通过以芳香环作为传送带的连续1,4-钯迁移来实现。该反应提供了一种有效的途径，可通过钯催化的远程CH活化/烯烃插入，芳基化，烯基化和Heck反应，以中等到良好的产率构建各种多环骨架。初步的机理研究表明，1,4-钯的迁移过程是可逆的。
• Indazole compounds useful as protein kinase inhibitors
  申请人：——

  公开号：US20040009968A1

  公开（公告）日：2004-01-15

  The present invention provides compounds of formula I: 1 or a pharmaceutically acceptable derivative thereof, wherein R 1 , R 2 , V 1 , V 2 , and V 3 are as described in the specification. These compounds are inhibitors of protein kinase, particularly inhibitors of AKT, PKA, PDK1, p70S6K, or ROCK kinase, mammalian protein kinases involved in proliferative and neurodegenerative disorders. The invention also provides pharmaceutical compositions comprising the compounds of the invention and methods of utilizing those compositions in the treatment of various disorders.

  本发明提供了公式I:1的化合物或其药用可接受的衍生物，其中R1、R2、V1、V2和V3如规范中描述。这些化合物是蛋白激酶的抑制剂，特别是AKT、PKA、PDK1、p70S6K或ROCK激酶的抑制剂，这些哺乳动物蛋白激酶参与增殖性和神经退行性疾病。该发明还提供了包括该发明的化合物的药物组合物以及利用这些组合物在治疗各种疾病中的方法。
• ABA RECEPTOR AGONISTS THAT MODULATE TRANSPIRATION
  申请人：The Regents of the University of California

  公开号：US20180146666A1

  公开（公告）日：2018-05-31

  The present invention provides agonist compounds that activate ABA receptors, agricultural formulations comprising the agonist compounds, and methods of use for the compounds and formulations. The agricultural formulations are useful for inducing ABA responses in plant vegetative tissues, reducing abiotic stress in plants, and inhibiting germination of plant seeds. The compounds are also useful for inducing expression of ABA-responsive genes in cells that express endogenous or heterologous ABA receptors.

  本发明提供了激活ABA受体的激动剂化合物，包括这些激动剂化合物的农业配方，以及这些化合物和配方的使用方法。这些农业配方可用于诱导植物的叶绿组织产生ABA反应，减轻植物的非生物胁迫，抑制植物种子的萌发。这些化合物还可用于诱导表达在表达内源或异源ABA受体的细胞中的ABA响应基因。
• Synthesis, Antimalarial Activity, and Molecular Modeling of Tebuquine Analogues
  作者：Paul M. O'Neill、David J. Willock、Shaun R. Hawley、Patrick G. Bray、Richard C. Storr、Stephen A. Ward、B. Kevin Park

  DOI：10.1021/jm960370r

  日期：1997.2.1

  amodiaquine (2) and chloroquine (1) both in vitro and in vivo. We have developed a novel more efficient synthetic route to tebuquine analogues which involves the use of a palladium-catalyzed Suzuki reaction to introduce the 4-chlorophenyl moiety into the 4-hydroxyaniline side chain. Using similar methodology, novel synthetic routes to fluorinated (7a, b) and a dehydroxylated (7c) analogue of tebuquine

  Tebuquine（5）是一种4-氨基喹啉，在体外和体内均显着高于阿莫二喹（2）和氯喹（1）。我们已经开发了一种新的更有效的合成戊喹类似物的合成路线，该路线涉及使用钯催化的Suzuki反应将4-氯苯基部分引入到4-羟基苯胺侧链中。使用相似的方法，还开发了新颖的合成路线来合成戊丁喹的氟化物（7a，b）和脱羟基化的（7c）类似物。对新型类似物进行了针对恶性疟原虫对氯喹敏感的HB3菌株和耐氯喹的K1菌株的测试。戊丁喹是针对两种疟原虫菌株测试的最具活性的化合物。用氟或氢取代4-羟基官能团导致抗疟活性降低。戊丁喹类似物与氨二喹和氯喹的分子模型研究表明，这类药物中分离的双质子化形式的氮间分离范围在9.36至9.86 A之间，而在血红素-药物复合物中则在7.52至10.21 A之间。关于4-氨基喹啉与拟议的细胞受体血红素相互作用的进一步模型研究表明，氯喹，氨二喹和戊丁喹类似物具有良好的相互作用能。在真空